Who are Sevoflurane - Neostigmine 70's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sevoflurane - Neostigmine 30.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sevoflurane-neostigmine-70.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Sevoflurane - Neostigmine 70 — Competitive Intelligence Brief

Sevoflurane - Neostigmine 70 (Sevoflurane - Neostigmine 70) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Volatile anesthetic with cholinesterase inhibitor. Area: Anesthesiology.

marketed Volatile anesthetic with cholinesterase inhibitor GABA receptors (sevoflurane); acetylcholinesterase (neostigmine) Anesthesiology Small molecule Live · refreshed every 30 min

Target snapshot

Sevoflurane - Neostigmine 70 (Sevoflurane - Neostigmine 70) — Pontificia Universidade Catolica de Sao Paulo. This is a combination of sevoflurane (a volatile anesthetic) and neostigmine (a cholinesterase inhibitor) used to maintain anesthesia and reverse neuromuscular blockade.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sevoflurane - Neostigmine 70 TARGET	Sevoflurane - Neostigmine 70	Pontificia Universidade Catolica de Sao Paulo	marketed	Volatile anesthetic with cholinesterase inhibitor	GABA receptors (sevoflurane); acetylcholinesterase (neostigmine)
Sevoflurane - Neostigmine 30	Sevoflurane - Neostigmine 30	Pontificia Universidade Catolica de Sao Paulo	marketed	Volatile anesthetic with cholinesterase inhibitor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Volatile anesthetic with cholinesterase inhibitor class)

Pontificia Universidade Catolica de Sao Paulo · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sevoflurane - Neostigmine 70 — Competitive Intelligence Brief. https://druglandscape.com/ci/sevoflurane-neostigmine-70. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab